ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc (ARQT)

9.91
0.32
(3.34%)
Closed March 29 04:00PM
9.91
0.00
(0.00%)
After Hours: 07:45PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
9.91
Bid
9.17
Ask
10.00
Volume
3,723,645
9.61 Day's Range 10.02
1.76 52 Week Range 15.40
Market Cap
Previous Close
9.59
Open
9.67
Last Trade
25
@
9.88
Last Trade Time
Financial Volume
$ 36,423,333
VWAP
9.7816
Average Volume (3m)
5,076,191
Shares Outstanding
96,813,363
Dividend Yield
-
PE Ratio
-3.07
Earnings Per Share (EPS)
-3.22
Revenue
3.69M
Net Profit
-311.46M

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targe... Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate, roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Arcutis Biotherapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ARQT. The last closing price for Arcutis Biotherapeutics was $9.59. Over the last year, Arcutis Biotherapeutics shares have traded in a share price range of $ 1.76 to $ 15.40.

Arcutis Biotherapeutics currently has 96,813,363 shares outstanding. The market capitalization of Arcutis Biotherapeutics is $957.48 million. Arcutis Biotherapeutics has a price to earnings ratio (PE ratio) of -3.07.

ARQT Latest News

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

WESTLAKE VILLAGE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful...

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

Industry veteran with over 25 years’ experience will continue to advance the company culture and grow the capabilities of Arcutis’ workforce WESTLAKE VILLAGE, Calif., March 11, 2024 (GLOBE...

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 139.4% of children...

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signatureSuggests skin barrier disruption in seborrheic dermatitis is distinct with its own...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.97-8.9154411764710.8811.049.0931700389.59795655CS
40.424.425711275039.4912.359.09463762710.48866868CS
125.92148.3709273183.9912.353.110150761917.568551CS
264.3377.59856630825.5812.351.7646975675.13266567CS
52-0.42-4.0658276863510.3315.41.7629325026.02036589CS
156-17.95-64.429289303727.8636.451.7612665159.11734801CS
260-13.14-57.006507592223.0540.881.7696259210.17741404CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

ARQT Discussion

View Posts
Denisk Denisk 4 days ago
Headed much lower
👍️0
Zorro Zorro 3 weeks ago
https://ih.advfn.com/stock-market/NASDAQ/arcutis-biotherapeutics-ARQT/stock-news/93458845/new-research-reveals-genomic-profile-of-seborrheic
👍️0
52172 52172 4 weeks ago
Headed much higher
👍️0
52172 52172 1 month ago
Some big buys ah
👍️0
ANTADOG ANTADOG 3 months ago
4,38~~ ANT
👍️0
ANTADOG ANTADOG 3 months ago
4,31~~ ANT
👍️0
ANTADOG ANTADOG 3 months ago
4,19~~ ANT
👍️0
ANTADOG ANTADOG 3 months ago
chart still intact after today, it's one of those stocks i really like and that's not only because of the recent fda approval, it's currently almost just between the 50 and 200ma, with that 50 ma curlin' up (2,44), i do hope u get more shares when the market allows it, i would add as well, but the best thing is: u got a starter, and we got an awesome chart, fyi ANT
👍️0
Denisk Denisk 3 months ago
Only have 150 shares at average of $2.72 a share. Maybe will buy another 100 if price goes below $3.00
👍️0
ANTADOG ANTADOG 3 months ago
one sell/profit takin' day after 3 buy days, and the way i see it, chart is still intact, ANT
👍️0
ANTADOG ANTADOG 3 months ago
arqt chart upward trend intact, higher highs higher lows since 2 bucks ( start December), fyi ANT
👍️0
ANTADOG ANTADOG 3 months ago
Arqt restless wants to visit 3,80's, imosho ANT
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 3 months ago
$ARQT
https://x.com/hannahadad8890/status/1740692333585367363?s=61
👍️0
saigai saigai 3 months ago
hello blue skies
👍️0
SmallCapValueInvestor SmallCapValueInvestor 3 months ago
High of day $3.49, maybe we break $4.00 today
👍️0
SmallCapValueInvestor SmallCapValueInvestor 3 months ago
High of day $3.21, currently trading at $3.05
👍️0
TraderX TraderX 3 months ago
Form 4 filed by CEO/President, if I'm reading this correctly.
👍️0
SmallCapValueInvestor SmallCapValueInvestor 3 months ago
Today's high was $2.93, I hope we can break $3 this week
👍️0
saigai saigai 3 months ago
2.55 looking awfully smart
👍️0
saigai saigai 3 months ago
zero downside risk from your entry
👍️0
SmallCapValueInvestor SmallCapValueInvestor 3 months ago
I entered $2.55 today
👍️0
saigai saigai 3 months ago
arqt it aint over till the big lady sings. lets close strong
👍️0
saigai saigai 3 months ago
3.19 i think i posted it in an earler post.. i have very little didcipline and more likely to chase early then wait for the inevitable retrace..
👍️0
SmallCapValueInvestor SmallCapValueInvestor 3 months ago
dipped to $2.48, I wonder if $2.44 will fill today.
👍️0
SmallCapValueInvestor SmallCapValueInvestor 3 months ago
What's your entry if you don't mind me asking
👍️0
saigai saigai 3 months ago
bad entry great stock.. ill make smoney here
👍️0
SmallCapValueInvestor SmallCapValueInvestor 3 months ago
Have a limit buy for $2.44, let's see
👍️0
subslover subslover 3 months ago
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration of use
ZORYVE foam provides rapid disease clearance and significant reduction in itch, one of the most burdensome symptoms of seborrheic dermatitis
First drug approved for seborrheic dermatitis with a new mechanism of action in over two decades
Seborrheic dermatitis affects more than 10 million people in the United States
Commercial product expected to be available by end of January
Management will host conference call on Monday, December 18 at 8:30 a.m. EST
WESTLAKE VILLAGE, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has approved the new drug application (NDA) for ZORYVE (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals 9 years of age and older. ZORYVE foam provides rapid disease clearance and significant reduction in itch, with nearly 80% of individuals achieving the primary efficacy endpoint of IGA Success and just over 50% of individuals reaching complete clearance at Week 8 in the STRATUM trial. ZORYVE is a once-daily steroid-free foam and the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.

“We know from dermatology clinicians and those living with seborrheic dermatitis that there has been a real struggle with disease clearance and treatment adherence due to lack of efficacy, difficulty treating certain body areas, inconvenient treatment regimens, and concerns about safety with long-term use,” said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis. “ZORYVE foam is a once-daily, steroid-free topical treatment that can be used anywhere on the body, including hair-bearing areas, with no limitation on duration of use. We are proud to deliver meaningful innovation through this approval of ZORYVE foam, and to offer a new topical treatment that effectively clears and controls the disease and can simplify its management for the millions of adults and adolescents living with seborrheic dermatitis.”

Seborrheic dermatitis affects more than 10 million people in the United States, and is a common, chronic, and recurrent inflammatory skin disease that causes red patches covered with large, greasy, flaking yellow-gray scales, and persistent itch. In individuals with darker skin tones, inflamed areas may not appear red, but instead can appear pink, slightly purple, or lighter in color than the surrounding skin. It occurs most often in areas of the body with oil-producing (sebaceous) glands, including the scalp, face (especially on the nose, eyebrows, ears, and eyelids), upper chest, and back. Hair-bearing areas make applying topicals like creams, gels, and ointments difficult.

“In the STRATUM trial, ZORYVE foam provided rapid disease clearance as early as Week 2 and significant itch relief in as little as 48 hours. In addition, almost 80% of patients achieved treatment success at Week 8. While multiple factors contribute to seborrheic dermatitis, inflammation and skin barrier dysfunction play key roles. ZORYVE has been shown to effectively reduce the signs of inflammation, redness, and scaling in patients with seborrheic dermatitis, and with its unique formulation, ZORYVE foam effectively delivers the drug without disrupting the skin barrier and has been shown to be safe and tolerable. ZORYVE foam is thus ideally formulated, having the potential to become the new standard of care for seborrheic dermatitis treatment,” said Andrew Blauvelt, MD, MBA, clinical investigator at Oregon Medical Research Center, and investigator on the STRATUM trial.

Beyond the appearance and irritation of physical symptoms, seborrheic dermatitis is associated with a decrease in quality of life and may negatively affect emotional well-being, self-esteem, and day-to-day life, including sleep and work. People with seborrheic dermatitis, and especially adolescents and school-age children, may suffer from social stigma, negative self-image, and low self-esteem associated with very visible skin diseases like seborrheic dermatitis.

“Approximately 10 million people in the United States have seborrheic dermatitis, but until today, there have been limited treatment options. We are thrilled with this FDA approval and are excited to bring to market a new, highly effective steroid-free topical formulation that can be used anywhere on the body,” said Frank Watanabe, president and CEO of Arcutis. “Our commercial team is ready and poised to launch ZORYVE foam very soon, and we are committed to ensuring affordable access to ZORYVE foam to those who may benefit from this novel treatment.”

Arcutis intends to make ZORYVE foam widely available via key wholesaler and dermatology pharmacy channels as a new treatment option by the end of January 2024. The Company is dedicated to responsible pricing and affordable access to therapy. The ZORYVE® Direct Program helps patients access their prescribed Arcutis medication. For patients with seborrheic dermatitis who have been prescribed ZORYVE, this patient support program helps patients navigate the payer process, assists patients with adherence, and includes the ZORYVE Direct Savings Card Program, which can help reduce out-of-pocket costs for eligible commercially insured patients.† Arcutis will also continue to offer the Arcutis CaresTM patient assistance program (PAP) that provides ZORYVE at no cost for financially eligible patients who are uninsured or underinsured.‡

Management will host a conference call on Monday, December 18 at 8:30 a.m. EST. A live webcast of the call and presentation material will be available on the “Events” section of the Company's Investor website. An archived version of the webcast will be available on the Arcutis website after the call.

ZORYVE Foam Clinical Data
The approval is supported by positive results from Arcutis’ Phase 2 and pivotal Phase 3 trials in seborrheic dermatitis. The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) and the Phase 2 (Trial 203) were parallel group, double-blind, vehicle-controlled studies evaluating the safety and efficacy of ZORYVE foam 0.3% in seborrheic dermatitis. Together the two studies enrolled 683 adults and adolescents ages 9 years and older.

The STRATUM study met its primary endpoint, with nearly 80% of ZORYVE foam treated individuals reaching Investigator Global Assessment (IGA) Success rate at Week 8 (79.5% ZORYVE foam vs 58.0% vehicle; P
👍️0
Gunner54 Gunner54 3 months ago
Sell us on this company, links are appreciated
👍️0
frans frans 3 months ago
FDA approval
👍️0

Your Recent History

Delayed Upgrade Clock